Table 1.
Compliance and completion rates for the EORTC QLQ-C30 questionnaire
| Time point | Expected forms, n | Compliance rate,a % | Completion rate,b % | |||
|---|---|---|---|---|---|---|
| Olaparib | TPC | Olaparib (n=205) | TPC (n=97) | Olaparib (n=205) | TPC (n=97) | |
| Baseline | 205 | 97 | 99.0 | 95.9 | 99.0 | 95.9 |
| Visit 6 (week 6) | 205 | 96 | 87.3 | 71.9 | 87.3 | 71.1 |
| Visit 8 (week 12) | 184 | 73 | 87.0 | 71.2 | 78.0 | 53.6 |
| Visit 10 (week 18) | 167 | 50 | 84.4 | 70.0 | 68.8 | 36.1 |
| Visit 12 (week 24) | 136 | 36 | 84.6 | 63.9 | 56.1 | 23.7 |
| Visit 14 (week 30) | 115 | 30 | 84.4 | 63.3 | 47.3 | 19.6 |
| All visits (overall)c | 205 | 97 | 93.2 | 76.3 | 93.2 | 76.3 |
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module; PRO, patient-reported outcome; TPC, treatment of physician’s choice.
Note that 19 assessments are included whereby the questionnaire was administered to a caregiver, relative, or unspecified person, rather than directly to the patient.
Compliance rate for each treatment arm was defined as (number of evaluable questionnaires [defined as a questionnaire with enough responses to score at least one scale/domain])/(number of patients expected to complete questionnaires at each visit [ie patients still under PRO follow-up]) × 100%.
Completion rate for each treatment arm was defined as (number of received questionnaires)/(PRO analysis population) × 100%.
For overall, patients were counted as received/evaluable if they had a received/evaluable baseline and at least one received/evaluable post-baseline form.